The truncated phage lysin CHAPk eliminates staphylococcus aureus in the nares of mice

Bioengineered Bugs

Volumn 1, Issue 6, 2010, Pages 404-407

  Fenton, Mark ^a   Casey, Pat G ^b   Hill, Colin ^b   Gahan, Cormac G M ^b   Ross, R Paul ^c   Mcauliffe, Olivia ^c   O'Mahony, Jim ^a   Maher, Fiona ^a   Coffey, Aidan ^a  

^a Ireland   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c TEAGASC FOOD RESEARCH CENTRE   (Ireland)

Author keywords

Bacteriophage; Decolonization; Lysin; Nasal; Staphylococcus

Indexed keywords

ANTIBIOTIC AGENT; CHAPK; KANAMYCIN; LYSINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ENDOLYSIN; HYDROLASE; PEPTIDE HYDROLASE; PROTEINASE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIOPHAGE; CELL SUSPENSION; CELL VIABILITY; NONHUMAN; NOSE MUCOSA; STAPHYLOCOCCUS AUREUS; ANIMAL; BACTERIOLYSIS; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; MOUSE; PHYSIOLOGY; STAPHYLOCOCCUS PHAGE;

MUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

AMINOHYDROLASES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOLYSIS; ENDOPEPTIDASES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NASAL MUCOSA; PEPTIDE HYDROLASES; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGES;

EID: 78650116072     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bbug.1.6.13422     Document Type: Article

References (32)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
2. European Antimicrobial Resistance Surveillance system. EARSS Annual Report 2005-2006; 1-47.
3. Van Rijen ML, Bonten M, Wenzel RP, Kluytmans J. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systemic review. J Antimicrob Chemother 2008; 61:254-61.
4. Kluytmans J, Van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms and associated risks. Clin Microbiol Rev 1997; 10:505-20.
5. Coates T, Bax R, Coates A. Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. Antimicrob Agents Chemother 2009; 64:9-15.
6. Loessner MJ. Bacteriophage endolysins-current state of research and applications. Curr Opin Microbiol 2005; 8:480-7.
7. Fenton M, Ross RP, McAuliffe O, O'Mahony J, Coffey A. Recombinant bacteriophage lysins as antibacterials. Bioengineered bugs 2010; 1:9-16.
8. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294:2170-2.
9. Zimmer M, Vukov N, Scherer S, Loessner MJ. The murein hydrolase of the bacteriophage phi3626 dual lysis system is active against all tested Clostridium perfringens strains. Appl Environ Microbiol 2002; 68:5311-7.
10. O'Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including Methicillin-Resistant Staphylococcus aureus. J Bacteriol 2005; 187:7161-4.
11. Loessner MJ, Maier SK, Daubek-Puza H, Windlinger G, Scherer S. Three Bacillus cereus bacteriophage endolysins are unrelated but reveal high homology to cell wall hydrolases from different bacilli. J Bacteriol 1997; 179:2845-51.
12. Cheng Q, Nelson D, Zhu Z, Fischetti VA. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 2005; 49:111-7.
13. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 2005; 49:4789-92.
14. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis 2008; 197:1519-22.
15. Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 2003; 52:967-73.
16. Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 2003; 71:6199-204.
17. McCullers JA, Karlstrom A, Iverson AR, Loeffler JM, Fischetti VA. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog 2007; 3:28.
18. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001; 98:4107-12.
19. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002; 418:884-9.
20. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, et al. Efficient elimination of multidrugresistant Staphylococcus aureus by cloned lysin derived from bacteriophage FMR11. J Infect Dis 2007; 196:1237-47.
21. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. Synergism between a novel chimeric lysin and oxacillin protects against infection by Methicillin- Resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54:1603-12.
22. Garcia P, Lopez R, Ronda C, Garcia E, Tomasz A. Mechanism of phage induced lysis in pneumococci. J Gen Microbiol 1983; 129:479-87.
23. Fischetti VA. Bacteriophage endolysins: a novel antiinfective to control Gram-positive pathogens. Int J Med Microbiol 2010; [Epub ahead of print].
24. Donovan DM, Lardeo M, Foster-Frey J. Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. FEMS Microbial Lett 2006; 265:133-9.
25. Obeso JM, Martinez B, Rodriguez A, Garcia P. Lytic activity of the recombinant staphylococcal bacteriophage phiH5 endolysin active against Staphylococcus aureus in milk. Int J Food Microbiol 2008; 128:211-8.
26. Becker SC, Foster-Frey J, Donovan DM. The phage K enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbial Lett 2008; 287:185-91.
27. Manoharadas S, Witte A, Blasi U. Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J. Biotechnol 2009; 139:118-23.
28. Sass P, Bierbaum G. Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol 2007; 73:347-52.
29. Horgan M, O'Flynn G, Garry J, Cooney J, Coffey A, Fitzgerald GF, et al. The phage lysin, LysK, can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci. Appl Environ Microbiol 2009; 75:872-4.
30. Xiong YQ, Willard J, Kadurugamuwa JL, Yu J, Francis KP, Bayer AS. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob Agents Chemother 2005; 49:380-7.
31. Yu J, Wu J, Francis KP, Purchio TF, Kadurugamuwa JL. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother 2005; 55:528-34.
32. Kadurugamuwa JL, Sin LV, Yu J, Francis KP, Purchio TF, Contag PR. Noninvasive optical imaging method to evaluate postantibiotic effects on biofilm infection in vivo. Antimicrob Agents Chemother 2004; 48:2283-7.